BioSpace News Archive

Ruben U. Carvajal, MD recently discovered an incident that may impact certain Ruben U. Carvajal, MD patient information.

AlloSource announced that it will award Dr. Kevin Shea with its second annual Dr. Steven Gitelis Inspiration Award.

Treatment Management Company, a leading provider of drug and alcohol treatment programs, has named Ray Velazquez as chief executive officer.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S FDA has approved SYMTUZA™, the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults.

On July 1, 2018, Attorney Christopher I. Jacobs of Kalfus & Nachman, P.C. was named a member of the Supreme Court of Virginia’s Medical Malpractice Review Panel (MMRP).

The JOBS and Investor Confidence Act of 2018, which includes the Fostering Innovation Act, provides much needed regulatory relief for pre-revenue innovators

National Life Insurance Company announced the expiration of and the results for its previously announced offer to exchange any and all of National Life’s outstanding 10.50% Surplus Notes due 2039 held by Eligible Holders

The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor

Polares Medical SA announced the closing of a $25 million financing led by Decheng Capital (Menlo Park and Shanghai) together with Endeavour Vision (Geneva), IDO Investments (Muscat), Earlybird Venture Capital (Berlin) and Wellington Partners (Munich).

The good news keeps coming for Janssen Pharmaceuticals’ SGLT2 diabetes drug Invokana. Late Monday the company said it was halting its Phase III chronic kidney disease trial early due to the fact that the drug had already achieved pre-specified efficacy data.